Latest News and Press Releases

Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and...

Business Update Current contracted value signed in 2023 of £124 million, an increase of 47% compared to £85 million in the year ending 31 December 2022 (excluding COVID-19 vaccine manufacturing)On...

Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO Oxford Biomedica announces the signing of a sale and purchase agreement...

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...

Oxford Biomedica to host webinar showcasing the TetraVectaTM system Oxford, UK – 07 September 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led...

Oxford Biomedica launches TetraVectaTM - the next generation lentiviral vector system Oxford, UK – 15 May 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and...

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director Oxford, UK – 26th April 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led...

Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023 Dr Mathias brings a wealth of experience in innovation, contract development and manufacturing to Oxford BiomedicaStuart...

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...